Vistagen Therapeutics (VTGN) Operating Income (2017 - 2025)
Historic Operating Income for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to -$19.5 million.
- Vistagen Therapeutics' Operating Income fell 2927.25% to -$19.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$69.9 million, marking a year-over-year decrease of 3228.99%. This contributed to the annual value of -$56.0 million for FY2025, which is 6950.73% down from last year.
- Vistagen Therapeutics' Operating Income amounted to -$19.5 million in Q4 2025, which was down 2927.25% from -$20.1 million recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Operating Income peaked at -$6.2 million during Q1 2021, and registered a low of -$20.1 million during Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' median Operating Income value was -$12.5 million (recorded in 2021), while the average stood at -$12.9 million.
- In the last 5 years, Vistagen Therapeutics' Operating Income plummeted by 28862.07% in 2021 and then skyrocketed by 6460.85% in 2023.
- Vistagen Therapeutics' Operating Income (Quarter) stood at -$10.5 million in 2021, then grew by 7.33% to -$9.8 million in 2022, then increased by 19.28% to -$7.9 million in 2023, then tumbled by 91.78% to -$15.1 million in 2024, then dropped by 29.27% to -$19.5 million in 2025.
- Its Operating Income was -$19.5 million in Q4 2025, compared to -$20.1 million in Q3 2025 and -$15.8 million in Q2 2025.